What is the story about?
Ichnos Glenmark Innovation, Inc. (IGI), a global clinical-stage biotechnology company focused on developing multispecific antibodies in oncology, has announced a new development candidate, ISB 2301, for the potential treatment of multiple solid tumour indications.
According to a press release filed with the NSE, the company said ISB 2301 is a first-in-class multispecific immune cell activator that targets three tumour-associated antigens to trigger tumour cell death while engaging both T cells and NK cells to activate the immune system.
IGI said ISB 2301 was developed using its proprietary BEAT platform technology. The company added that the candidate is designed to induce antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition and a sustained type-1 immune response.
“We engineered ISB 2301 to match the biological complexity of solid tumours in a way that conventional immunotherapies have not been able to address,” said Lida Pacaud, MD, President and Chief Executive Officer (CEO).
“By simultaneously targeting three tumour-associated antigens and engaging both T cells and NK cells, it deploys a level of multi-mechanistic precision that we believe sets a new benchmark for what multispecific antibodies can achieve in solid tumours,” she added.
The company said it intends to file an Investigational New Drug (IND) application by the end of this year and begin clinical studies in 2027.
Glenmark Pharmaceuticals Limited informed stock exchanges about the development through a regulatory filing on Wednesday.
Also Read: Eris Life Q4 Results: Stock gains 12% as Domestic Branded Formulations leads growth
Shares of Glenmark Pharma closed at ₹2,370 on the NSE on Wednesday, down ₹35.90 or 1.49% from the previous close.
Also Read: Aditya Birla Capital raises ₹4,000 crore to fund growth, confirms CNBC-TV18 Newsbreak
According to a press release filed with the NSE, the company said ISB 2301 is a first-in-class multispecific immune cell activator that targets three tumour-associated antigens to trigger tumour cell death while engaging both T cells and NK cells to activate the immune system.
IGI said ISB 2301 was developed using its proprietary BEAT platform technology. The company added that the candidate is designed to induce antibody-dependent cellular cytotoxicity (ADCC), checkpoint inhibition and a sustained type-1 immune response.
“We engineered ISB 2301 to match the biological complexity of solid tumours in a way that conventional immunotherapies have not been able to address,” said Lida Pacaud, MD, President and Chief Executive Officer (CEO).
“By simultaneously targeting three tumour-associated antigens and engaging both T cells and NK cells, it deploys a level of multi-mechanistic precision that we believe sets a new benchmark for what multispecific antibodies can achieve in solid tumours,” she added.
The company said it intends to file an Investigational New Drug (IND) application by the end of this year and begin clinical studies in 2027.
Glenmark Pharmaceuticals Limited informed stock exchanges about the development through a regulatory filing on Wednesday.
Also Read: Eris Life Q4 Results: Stock gains 12% as Domestic Branded Formulations leads growth
Shares of Glenmark Pharma closed at ₹2,370 on the NSE on Wednesday, down ₹35.90 or 1.49% from the previous close.
Also Read: Aditya Birla Capital raises ₹4,000 crore to fund growth, confirms CNBC-TV18 Newsbreak
